IBM Research collaborated with CHDI Foundation, a non-profit biomedical research organization to develop therapeutics that could substantially improve the lives of those affected by Huntington’s Disease (HD.)
People with HD show symptoms that start as subtle cognitive and motor changes, but gradually develop into uncontrollable movements and dementia before eventually leading to death. There is great variability in the time of onset of these symptoms and their pace. This means that, even with the genetic tests available, there is a need to reduce uncertainty about the state and future of individual patients for their own life plans. Also critical are clinical trials that can potentially help treat those impacted by the disease. A potential route to progress is using techniques from AI that can learn patterns present in different clinical measures to extract insights about the present state of patients and their likely progression.
In a study published today in the Scientific Reports journal by Nature Research, IBM and CHDI researchers studied the relationship between the pace of subtle cognitive decline in patients before full-fledged symptoms and their brain activity, as shown by a functional MRI. The results demonstrate that measuring the potential progression of HD could eventually be done from a single brain scan, acquired in one visit.
An important part of the collaboration between IBM Research and CHDI is developing AI models that learn patterns present in brain images that can provide individualized information about progression.
Devastating as it is, from a technical point of view HD displays a number of features that distinguish it from other neurodegenerative disorders and not only guide treatment design, but also help us to better understand the disease. In particular, genetic tests make it possible to study its progression many years before the onset of symptoms. In fact, several large studies followed hundreds of people with and without the HD mutation over time. This set-up is optimal for building AI models that can learn the earliest signs of the disease in the brain and can inform ongoing and future clinical changes.
IBM Researchers used data from one of these studies (TRACK-HD) to ask what information is present about the disorder in functional MRI scans, which record activity in the whole brain. Even when one is “doing nothing” (what neuroscientists call the “resting state”), the brain is always active. Some areas of the brain tend to become active in synchrony, while others tend to be more active when others become inactive.
The team used AI techniques designed to extract data about ongoing cognitive changes present in these patterns of coactivation, which can be very subtle. This involved building a high-resolution network of the brain from resting-state activity, where functional connections are defined by high correlations between network nodes. Then, the reseachers built maps that ranked the centrality or importance of each node in each individual brain. They showed that these maps provide a reliable neurological signature, even when remeasured one or two years later.
Using interpretable AI models, the researchers demonstrated that these patterns can indicate how fast cognitive changes are beginning to take place. They applied a simple logistic regression model, modified to select from the whole brain only the most relevant nodes. These models could reliably identify extreme subgroups of patients that were either stable or showing rapid decline. Additionally, these same models could provide a continuous estimate of the rate of the decline, which remained valid even when looking at data from hospitals that were not considered during model training. Having this robust estimate is important, because detecting slow and subtle clinical change is challenging, and can take many yearly visits to the doctor.
A rationale for the potential use of AI models to predict progression of HD. A single MRI measurement would be obtained on an individual that has not shown full symptoms. From this measurement of brain activity, the structure of a brain network would be estimated. The AI model would learn to use this network to distinguish patients that are stable from those starting to show cognitive decline. Patients in which ongoing change is expected could receive treatment and their evolution could be compared against an expected individualized trajectory, increasing ability to detect treatment effects during trials.
This approach has several potential applications, in particular for the design of clinical trials. If successful, candidate therapeutics could be evaluated in people who are only just beginning to develop symptoms, when there is probably the best opportunity to slow progression, but without testing therapeutics in people who are completely symptom-free and stable and in whom the effectiveness of a new treatment would be impossible to detect.